YAP1 and McLeod neuroacanthocytosis syndrome: Pharmacologic inhibition of YAP1 activity with verteporfin was shown to suppress MLS cell viability in vitro and in vivo, rendering YAP1 a molecular target for therapeutic intervention in MLS [15, 18].